PLx Pharma (Dipexium Pharmaceuticals)
Priced, Nasdaq: PLXPLate-stage biotech developing a topical antibiotic for diabetic foot ulcer infections.
Industry: Health Care
First Day Return: +17.0%
PLXP
Late-stage biotech developing a topical antibiotic for diabetic foot ulcer infections.
| IPO Date | 03/12/2014 |
|---|---|
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $33 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| IPO Intelligence Only |
| Headquarters | New York, NY, United States |
|---|---|
| Founded | 2010 |
| Employees at IPO | 7 |
| Website www.dipexiumpharmaceuticals.com | |
IPO News for PLx Pharma (Dipexium Pharmaceuticals)
PLx Pharma (Dipexium Pharmaceuticals) (PLXP) Performance
